Loading...
•
Mar 31, 2025
Rxsight Q1 2025 Earnings Report
Reported first quarter 2025 financial results
Key Takeaways
RxSight, Inc. reported strong first quarter 2025 results with significant revenue growth driven by increased sales of Light Adjustable Lenses and Light Delivery Devices. The company reiterated its full-year 2025 guidance.
Total revenue for Q1 2025 was $37.9 million, a 28% increase compared to Q1 2024.
Light Adjustable Lens (LAL) procedure volume increased by 36% in Q1 2025 compared to the prior year period.
The installed base of Light Delivery Devices (LDD) grew to 1,044 as of March 31, 2025, a 43% expansion year-over-year.
Gross profit improved to $28.3 million, or 74.8% of revenue, in Q1 2025.
Forward Guidance
The company reiterated its full-year 2025 guidance for revenue, gross margin, and operating expenses.
Positive Outlook
- Continued enthusiasm for the Light Adjustable Lens among cataract surgeons is expected to drive growth.
- Strong customer and patient interest supports anticipated growth.
- An innovative product pipeline is expected to contribute to future growth.
- Expansion of third-party light treatment service center business models is a positive factor.
- Recent international regulatory approvals are expected to support international expansion.
Challenges Ahead
- No specific negative factors were highlighted in the forward guidance section.
- No specific negative factors were highlighted in the forward guidance section.
- No specific negative factors were highlighted in the forward guidance section.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...